• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Med Res . Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study

tetano

Editor, Senior Moderator
Respir Med Res


. 2022 Mar 3;81:100900.
doi: 10.1016/j.resmer.2022.100900. Online ahead of print.
Characteristics and outcomes of COVID-19 patients with IPF: A multi-center retrospective study


Aykut Cilli[SUP] 1 [/SUP], Ismail Hanta[SUP] 2 [/SUP], Fatih Uzer[SUP] 3 [/SUP], Funda Coskun[SUP] 4 [/SUP], Can Sevinc[SUP] 5 [/SUP], Pelin Pınar Deniz[SUP] 2 [/SUP], Mehmet Parlak[SUP] 3 [/SUP], Ersoy Altunok[SUP] 2 [/SUP], Kemal Can Tertemiz[SUP] 5 [/SUP], Ahmet Ursavas[SUP] 4 [/SUP]



Affiliations
Free PMC article

Abstract

Background: There are few data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) infection in patients with idiopathic pulmonary fibrosis (IPF). The objective of this study is to describe the characteristics and outcomes of IPF patients confirmed COVID-19 infection.
Methods: In this retrospective, multi-center, cohort study, patients from 4 hospital medical records with known IPF and a COVID-19 diagnosis were identified. Demographic and clinical outcome data were abstracted through a review of electronic medical records.
Results: Records for 46 patients with IPF and COVID-19 were abstracted. The mean age was 65±10 years. The most common symptom was dyspnea, followed by fever and cough. Ground-glass opacities (n = 35, 83.3%) and consolidations (n = 11, 26.1%) were the main imaging features of the disease in thorax computed tomography (CT). Twenty-four patients (52.1%) required hospitalization. Among the hospitalized patients, 16 (66.6%) were admitted to the intensive care unit (ICU), and 10 (41.6%) underwent invasive mechanical ventilation. Thirteen patients (28.2%) died of COVID-19 complications. Mortality rate was significantly associated with lower DLCO/VA, long term oxygen therapy and consolidation finding on CT of thorax (p<0.05). On multivariable analysis, neither factor was associated with hospitalization or mortality.
Conclusions: IPF patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, ICU requirement, and mortality rate. Measures to minimize the risk of COVID-19 infection remain key to protect IPF patients.

Keywords: Idiopathic pulmonary fibrosis; Interstitial lung disease; Outbreak; Pandemic; SARS-CoV-2.
 
Back
Top Bottom